Repositioning of Eugenol in Treatment of Gastric Ulcers Through Development of Floating In situ Gel

  Theoral liquid dosage forms are more prone to low bioavailability because of their quick transit from the stomach. Producing sustained release formulation of an oral liquid dosage formcould be successfully augmented through a strategy of liquid in-situ gelling system. In-situ forming polymeric formulation is in sol form before administration in the body, but once administered undergoes in-situ gelation. The objective of this study was to develop a novel in-situ gel system of eugenol for treatment of peptic ulcer. Protective effect of eugenol against ulcer is documented but less practiced. The delivery system consists of varying concentrations of sodium alginate, gellan gum and calcium carbonate. The system was subjected to various in vitro and in vivo characterizations. In vitro release studies were conducted in 0.1 N HCl containing 5% of sodium lauryl sulphate. The finalised formulation (F16) contained gellan gum (0.5% w/v), calcium carbonate (1% w/v), sodium citrate (0.25% w/v) and mannitol (0.16% w/v). It showed drug release of 97.26%. The floating lag time was found to be less than 1 minute and system was found to be floating throughout the drug release time of 12 h. The gelation occurred immediately after addition in acidic medium. The pharmacodynamics studies on F16 exhibited gastro protective activity. The standard drug omeprazole showed 62.23 ± 0.63% inhibition of ulceration while formulation F16 showed 70.06 ± 0.81% inhibition of ulceration. The in vivo X-Ray studies revels that formulation shows formation of gel in acidic environment of stomach along with floating of gel.